Loading data for ANIP — first visit, this takes a few seconds.

ANI Pharmaceuticals, Inc. (ANIP)

NasdaqGM: ANIP · 即時價格 · USD

70.70

+0.47 (0.67%)

收盤價： Sep 11, 2026, 8:00 PM

70.19

+0.00%

盤後: 7:30 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

無可用資料

買價	56.91
市值	1.61B
營收 (ttm)	978M
淨利（ttm）	99.6M
	0.45
	4.52
	15.29
	6.69
P/B (ttm)	2.52
P/S (ttm)	1.65
財報日期	Nov 6, 2026

賣價	103.53
成交量	298,236
20 日平均成交量	343,763
開盤價	70.23
前收盤價	70.23
當日區間	70.00 - 70.92
52 週範圍	69.96 - 99.39
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 ANIP

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to nat...

類股 Healthcare

IPO 日期 May 5, 2000

員工 970

證券交易所 NasdaqGM

股票代號 ANIP

網站 https://www.anipharmaceuticals.com

完整的公司簡介

財務表現

ANI Pharmaceuticals 在 2025 年的營收為 883.37M，較前一年的 614.38M 增加 43.78%。淨利為 78.34M，較前期減少 -522.94%。

財務報表

財報驚奇

ANI Pharmaceuticals 已於 Aug 7, 2026 公布季度財報：

營收為 $266.04M 低於預期 $0, 年增 25.87% 成長.
每股盈餘為 2.21 超出預期 0.17, 年增 22.78% 成長.

下次財報發布

ANI Pharmaceuticals, Inc. 的下次財報預計於 Nov 6, 2026, 開盤前。
分析師預估營收 ... 升級

價格為何變動

新聞動態

2 週前 · StockStory

2 Reasons to Like ANIP (and 1 Not So Much)

ANI Pharmaceuticals currently trades at $76.15 per share and has shown little upside over the past six months, posting a middling return of 3%. The stock also fell short of the S&P 500’s 11.7% gain du...

2 週前 · StockStory

1 Russell 2000 Stock to Target This Week and 2 We Brush Off

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these ...

3 週前 · StockStory

The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q2 Earnings Call

ANI Pharmaceuticals’ second quarter was marked by strong year-on-year growth in its rare disease and generics businesses, but the market reacted negatively to the results. Management highlighted the r...

3 週前 · StockStory

Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ANI Pharmaceuticals (NASDAQ:ANIP) and the b...

4 週前 · Zacks

Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?

ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.

第 1 頁，共 2 頁

ANI Pharmaceuticals, Inc. (ANIP)